Gainers Buzz: US Airways Group, PulteGroup, Inc.(NYSE:PHM), Valeant Pharmaceuticals, Life Technologies Corp. (NASDAQ:LIFE)

Lakeway, NY -- (SBWIRE) -- 03/21/2013 -- ThePennyStockProfiler.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-

US Airways Group, Inc.(NYSE:LCC) shares increased 2.68% to $17.23. Raymond James lowered shares of LCC from an outperform rating to a market perform rating in a research report released on Mar. 19. Raymond James currently has $17.00 price target on the stock. Additionally, analysts at JPMorgan Chase upgraded shares of US Airways Group from a neutral rating to an overweight rating in a research note to investors on February 21. They now have a $18.50 price target on the stock, up previously from $18.00.

Is LCC a Still a Buy after the Solid momentum? Let’s Find out Here

PulteGroup, Inc.(NYSE:PHM) shares jumped 2.69% to $21.38. Zacks reissued their neutral rating on shares of PHM in a report released on Mar. 12. Zacks currently has a $21.00 target price on the stock. Separately, analysts at TheStreet reiterated a buy rating on shares of PulteGroup in a research note to investors this week.

Is PHM a Strong Buying Opportunity After The Recent Slump? Find out Here

Valeant Pharmaceuticals Intl Inc(NYSE:VRX) shares gained 2.65% to $73.33. Obagi Medical Products, Inc (NASDAQ: OMPI) on Mar. 20 announced that it entered into a definitive merger agreement with Valeant Pharmaceuticals under which Valeant will acquire all of the outstanding common stock of Obagi for $19.75 per share in cash. The transaction, which values Obagi common stock at approximately $360 million, was unanimously approved by the Obagi Board of Directors.

Should VRX Buy After The Recent Movement? Let’s Find out Here

Life Technologies Corp. (NASDAQ:LIFE) shares climbed 2.66% and closed at $65.27. Quidel Corporation QDEL and Life Technologies Corporation announced on Mar. 20 that they received 510(k) clearances from the United States Food and Drug Administration (FDA) to market the Quidel Molecular Direct C. difficile Assay with Life Technologies' QuantStudio(TM) Dx and 7500 Fast Dx Applied Biosystems(R) Real-Time PCR Instruments.

Should LIFE Buy After The Recent Movement? Let’s Find out Here

About ThePennyStockProfiler.com
ThePennyStockProfiler.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. ThePennyStockProfiler.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed "informational edge" which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at http://www.ThePennyStockProfiler.com

Disclaimer
The assembled information disseminated by ThePennyStockProfiler.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. ThePennyStockProfiler.com does expect that investors will buy and sell securities based on information assembled and presented in phd-trading.com. PLEASE always do your own due diligence, and consult your financial advisor.